Chris Edlin, Director at Pharmaceutical Manufacturing Technology Centre

.

Chris Edlin

Director at Pharmaceutical Manufacturing Technology Centre

• Pharmaceutical Manufacturing Technology Centre
  University of Limerick,
  Castletroy,
  Limerick,
  Ireland
• Telephone: +353 61 202293
• Email: chris.edlin@ul.ie

links

https://ie.linkedin.com/in/chrisedlin

cedlin101 (SKYPE)

http://www.pmtc.ie/
 https://www.facebook.com/chris.edlin

Summary

Experienced Research Director, fundraiser and CSO/CEO who has held leadership positions with Sanofi-Aventis, GSK, Roche, Medical Research Council Technology, iThemba Pharmaceuticals and PMTC.

Key Achievements:

• Grew start up from 3 to >25 FTEs
• Established and grew, from grass roots, an international chemistry CRO business with $MM turnover
• Delivered multiple clinical candidates across a variety of therapeutic areas
• Identified, built and funded multiple $MM international projects between Industry, Academia and PPPs

Strong communication, marketing, management and strategic thinking skills. Extensive and robust experience in forming networks and relationships and working across diverse cultures, levels and backgrounds.

Specialties: Production and delivery of business plans, Creating laboratory infrastructure, Hiring senior staff, Board level communication and facilitation, Team building, Innovation optimisation, Synthetic chemistry problem solving, Managing drug discovery and contract research projects, Project Management, Matrix leadership, Stake holder management, Strategy implementation, Neglected disease research, Technology assessment and delivery.

New appointment to lead on partnerships between medical research and industry

Chris Edlin joins as Head of Enterprise Research Partnerships for the College of Medicine, Biological Sciences & Psychology

Chris has joined the University of Leicester as Head of Enterprise Research Partnerships for The College of Medicine, Biological Sciences & Psychology, based in the Enterprise and Business Development Office.  He will primarily be responsible for developing new and expanding existing relationships between College research groups and industrial research partners and will take a leading role in assessing the industrial partnership potential of current research strengths across the College and accelerate the development of these enterprise opportunities.

Chris has previously held positions as Chief Scientific Officer at iThemba Pharmaceuticals (Johannesburg, South Africa), Group Leader (Medicinal Chemistry) with the Medical Research Council Technology, Team Leader (Medicinal Chemistry) with GSK and Roche Pharmaceuticals and Senior Medicinal Chemist with Sanofi Aventis.

Chris’s background in drug discovery has given him the opportunity to contribute to a broad range of activities from lead generation to the identification of clinical candidates across a number of different therapeutic areas including inflammation, respiratory diseases, HIV and infectious diseases working directly on multiple different target types (e.g. GPCRs, kinases and enzymes). Furthermore, he has considerable experience in managing drug discovery and contract research projects, matrix leadership, technology assessment and implementation, writing business plans, creating laboratory infrastructure, board level communication, intellectual property assessment and due diligence

He holds a first class degree in Chemistry and a PhD in Organic Chemistry, both awarded by the University of Durham, and is the author of over 40 scientific publications and patents.  He was elected as a Fellow of the Royal Society of Chemistry in 2012.\

Experience

Director

Pharmaceutical Manufacturing Technology Centre

March 2014 – Present (1 year 11 months)Limerick

Director of a new Centre in Pharmaceutical Manufacturing hosted at the University of Limerick (UL), with an ambitious research and development program. With seed funding from Enterprise Ireland, IDA and an industrial consortium of Irish and multinational companies the Centre will conduct innovative, high quality research in pharmaceutical manufacturing that has direct relevance to industry.

I am responsible for the overall direction, financial control (full P&L) and management of the research in the Centre. I am also responsible for delivering a five-year business plan with defined success metrics and research outcomes that are consistent with this business plan. Critical to the role is taking a leadership role in fostering pharmaceutical manufacturing research at a national and international level, in conjunction with industrial and academic partners, and funding agencies.

The Pharmaceutical Manufacturing Technology Centre (PMTC) is hosted by the University of Limerick with core funding of €1M per annum from the Irish government (Enterprise Ireland and the IDA Ireland). Income is supplemented with co-funding from industry and other public sources.

PMTC, established in December 2013, is led by an industry steering board with an active research program driven by its industry members. Companies access PMTC to create projects and execute world-beating industry-relevant research in advanced technology solutions to address contemporary manufacturing issues.

Head of Enterprise Research Partnerships

University of Leicester

December 2012 – January 2014 (1 year 2 months)Leicester, United Kingdom

Chief Scientific Officer

iThemba Pharmaceuticals

October 2009 – December 2012 (3 years 3 months)Johannesburg Area, South Africa

Responsible for project identification and funding in neglected diseases with a primary focus on TB discovery and HIV process innovation. Multiple international collaborative projects initiated and transitioned into H2L and LO. Most senior company officer with full P&L responsibility. Also responsible for fund raising, board and scientific advisory committee communication and company infrastructure and strategy.

Built and grew ($$MM turnover) a contract research division offering H2L and LO chemistry services from South Africa to a range of local and international clients

Director of Chemistry

iThemba Pharmaceuticals

July 2008 – October 2009 (1 year 4 months)Johannesburg Area, South Africa

Group Leader

MRCT

February 2006 – July 2008 (2 years 6 months)London, United Kingdom

Principal Scientist

GSK

February 2002 – January 2006 (4 years)Stevenage, United Kingdom

Team Leader

Roche

2001 – 2002 (1 year)Welwyn Garden City, United Kingdom

Senior Medicinal Chemist

sanofi-aventis

1998 – 2000 (2 years)London, United Kingdom

Education

University of Limerick

Master of Business Administration (M.B.A.) 

2015 – 2017

Durham University

PhD, Chemistry

1995 – 1998

Durham University

BSc, Chemistry

1992 – 1995

First class honours
Awarded ICI scholarship for academic achievement

Honors & Awards

Fellow of the Royal Society of Chemistry

Royal Society of Chemistry

October 2011

Associated Professor of Chemistry at the University of the Free State

University of the Free State

June 2011

African Network for Drug Discovery and Diagnostic Innovation Centre of Excellence

World Health Organisation (via ANDI)

September 2011

UL Hosts New €5M Pharmaceutical Manufacturing Technology Centre

Ul Hosts New €5m Pharmaceutical Manufacturing Technology Centre

The Minister for Skills, Research and Innovation, Damien English TD, recently launched the Pharmaceutical Manufacturing Technology Centre (PMTC) which will be headquartered at the University of Limerick. The State, through the Department of Jobs, Enterprise & Innovation, is investing €5M over the next 5 years in this industry-focussed Centre which will deliver advanced technology solutions to contemporary manufacturing issues currently challenging the Irish pharmaceutical sector. PMTC is the latest of 15 state-supported Technology Centres established jointly by Enterprise Ireland and IDA Ireland. The Centre brings together 24 industry partners and 9 Higher Education Institutes who will deliver the research.

The aim of PMTC is to make Ireland the global hub of pharmaceutical process innovation and manufacturing and ultimately support an industry which directly employs over 25,000 people. Manufacturing cost competitiveness and patent expiry are among the two most critical issues which threaten the future of this industry which contributes over €40BN in Irish exports per annum. The industry consortium currently comprises a mix of indigenous multinational pharmaceutical companies and SME’s including: Alkermes, Allergan Pharmaceutical, Applied Process Consulting, Astellas, Bristol-Myers Squibb Swords, Crest Solutions, Eli Lilly, Gilead, GSK, Helsinn Birex, Innopharma Labs, Janssen, Label Art, Leo Pharma, Merck Sharp Dohme, Pfizer, Process Analytics, Roche, Servier, Sigmoid Pharma, Takeda Pharmaceuticals, Techno-Path, Teva Pharmaceuticals and TopChem Pharma.

Pictured above are: Dr Chris Edlin, Director, PMTC, Minister Damien English, Dr Mary Shire, Vice President Research, UL, Professor Gavin Walker, Bernal Chair of Pharmaceutical Powder Engineering, UL and PMTC Research Team

• 2014
• October 2014

PMTC launch Good Cleaning Validation document at inaugural Knowledge Day event




Dr. Chris Edlin and Prof. Gavin Walker pictured at the launch of the Good Cleaning Validation document. (Photo: Alan Place FusionShooters)
Responding directly to key areas of concern and interest relating to cleaning validation identified by attendees at their 2014 cleaning workshop PMTC commissioned The Compliance Group to deliver a ‘good cleaning validation practice (GCVP)’ document.  Based on a review of current guidelines and input from HPRA, PharmaChemical Ireland, cleaning validation sub-teams and other Industry members t is now available to download on www.pmtc.ie.  A companion app is in preparation and will be available in the near future.


The document was launched at the very successful inaugural PMTC Knowledge Day event held in the Kemmy Business School on 28th August 2015. The event showcased the state funded, industry informed research programs in the centre.  It also provided a unique forum for networking with industrial and
academic colleagues working at the cutting edge of pharmaceutical innovation in Ireland.  Presentations, by PMTC researchers and industrialists covered areas including powder modelling for tablet processing and 3D printing and advanced manufacturing technologies.  We were pleased to
host key note speakers including John Lynch (Director of Compliance HPRA), Martin Wallace (GSK), Stan O’Neill (The Compliance Group) and Charles Gordon (Britest). Poster sessions, highlighting recent research developments, also took place alongside vendor and partner companies exhibits.  Companies and technology centres represented included Zenith Ireland, STERIS, InnopharmaLabs, Britest, BARD (UCC), Antech, Topchem Pharma, ALMAC, SSPC and DPTC. 




PMTC continues to strategically focus on developing advanced technology solutions for challenges facing all stages of pharmaceutical manufacturing.

 

 
 

 .



• 
  

Emma R Parmee, Associate Vice President, Head of Exploratory Chemistry at Merck

Emma R Parmee

Associate Vice President, Head of Exploratory Chemistry at Merck

https://www.linkedin.com/in/emma-r-parmee-4b945315

Summary

Emma Parmee is an Associate Vice President leading the Exploratory Chemistry Group at Merck and Co.. In that capacity she is responsible for a cross-network group whose role is to identify and advance novel projects to the Lead Optimization stage gate. Previously, she was head of the Discovery Chemistry Department at Merck & Co.'s West Point, PA. Until 2010 she was in the Medicinal Chemistry department at Merck & Co., Rahway, NJ., where she rose to the level of Senior Director, working in Cardiometabolic Diseases. She obtained her Bachelor's and Doctoral degrees in Organic Chemistry from Oxford University in the U.K. She then came to the U.S. and held a NATO Postdoctoral position at MIT where her work focused on the development of novel catalytic asymmetric aldol reactions. Emma has over twenty years of experience in the Pharmaceutical industry working in numerous therapeutic areas.

Emma Parmee is a British chemist and research scientist who is a co-inventor of numerous drug patents. She was one of the leading researchers in the development of sitagliptin and was awarded a Thomas Alva Edison Patent Award in 2007 and the Society of Chemical Industry's Gordon E Moore Medal in 2009 for her contributions.

Invited Keynote Industry Speaker Dr. Emma R. Parmee......Boston WInCS 2014

Emma Parmee
Emma Parmee at the award of the 2009 Gordon E Moore Medal
Nationality	British
Other names	Emma Rachel Parmee
Alma mater	University of Oxford Massachusetts Institute of Technology
Occupation	scientist
Employer	Merck & Co.

Experience

Associate Vice President, Head of Exploratory Chemistry

Merck

November 2013 – Present (2 years 3 months)Weat Point, PA

Associate Vice President, Discovery Chemistry Site Head - West Point

Merck

August 2012 – Present (3 years 6 months)

Executive Director, Discovery Chemistry Site Head - WP

Merck

August 2010 – August 2012 (2 years 1 month)

Senior Director

Merck

1992 – November 2010 (18 years)

Education

Massachusetts Institute of Technology

Post Doc, Synthetic Chemistry

1990 – 1992

University of Oxford

BA/PhD, Organic Chemistry

1983 – 1990

Biography

Emma Rachel Parmee was born in the United Kingdom obtaining a BA and PhD at the University of Oxford in chemistry.^[1] She completed her thesis in 1990^[2] and was awarded a NATO post-doctoral fellowship. She moved to the United States to complete her post-doctoral work under Saturo Masamune at the Massachusetts Institute of Technology, studying catalysts of asymmetric synthesis for aldol reactions. She completed her post-doctoral research in 1992 and joined Merck & Co. that same year working at their research laboratory in Rahway, New Jersey.^[1]

In 2006, Parmee was one of the lead investigators in the discovery of the selective Dipeptidyl peptidase-4 inhibitor sitagliptin(marketed by Merck under the trade name Januvia). The drug is used to treat Type 2 Diabetes and provides glucose lowering benefits without the side effects of some of the previously available treatments.^[3] Her involvement was recognized by the award of the Thomas Alva Edison Patent Award from the Research and Development Council of New Jersey,^[4] the Prix Galien^[5] for Endocrinology in 2007^[6] and the receipt of the 2009 Gordon E Moore Medal from the Society of Chemical Industry.^[3] In 2010, Parmee left the Rahway lab and moved to the facility at West Point, Pennsylvania where she served as the site lead for chemical discovery until 2013. She was then promoted to Associate Vice President and Head of Exploratory Chemistry . She also serves as the co-chair of the Early Discovery Council for Merck Research Laboratories. She has written more than forty papers which have appeared in peer-reviewed publications and has filed for over thirty US patents on her work.^[7]

7 Aug 2009 [cached]

Emma Parmee to Receive 2009 Gordon E. Moore MedalParmee to be honored for playing a key role in the discovery of the dipeptidyl peptidase 4 (DPP-4) inhibitor Januvia.
PHILADELPHIA, PA—7 August 2009—The Society of Chemical Industry (SCI), America Section, will award the SCI Gordon E. Moore Medal to Emma Parmee, director of medicinal chemistry at Merck. She will be presented with the medal at the Gordon E. Moore Ceremony and Luncheon on 15 September, during Innovation Day 2009 at the Chemical Heritage Foundation (CHF) in Philadelphia. Innovation Day gathers more than 200 leaders from the molecular-sciences industries to discuss cutting edge research.
Parmee is being awarded the SCI Moore Medal for playing a key role in the discovery of the dipeptidyl peptidase 4 (DPP-4) inhibitor Januvia (sitagliptin), the first and only DPP-4 inhibitor approved for the treatment of type 2 diabetes mellitus.Parmee and her colleagues' discovery represents a major advance in the treatment of type 2 diabetes. Because of its unique glucose-dependent mechanism of action, there is very low risk of hypoglycemia. Overall side effects are comparable to placebo, and unlike many other anti-hyperglycemic agents, Januvia does not cause weight gain. In addition, DPP-4 inhibition is associated with improvements in β-cell function, which may lead to increased long-term effectiveness.
"Emma Parmee's groundbreaking work has created an enduring legacy of better lives for millions of diabetics," said Andrew Liveris, SCI chairman and CEO of The Dow Chemical Company.

...

About Emma Parmee Parmee joined Merck following a stellar graduate career at Oxford and a NATO postdoctoral fellowship at MIT. She is co-inventor on the issued US patent covering Januvia and she received a Key Contributor Award from Merck for her many contributions to the DPP-4 program.She has lectured both nationally and internationally on herwork in this field and has authored six DPP-4 manuscripts, including four as first or senior author.
In addition to her contributions to the discovery of Januvia,Parmee and her team identified a subnanomolar, exquisitely selective DPP-4 inhibitor which was key in evaluating the benefits of selective inhibition. For example, using this inhibitor, her biological colleagues showed that inhibition of related proline peptidases, but not DPP-4, leads to T-cell activation. She also designed and prepared ligands for affinity columns which were used to purify DPP-4 and the related enzymes QPP and DPP-4β, subsequently identified as DPP-8. The latter enzyme was shown to be responsible for the toxicity observed in preclinical species with nonselectiveDPP-4 inhibitors.
Following the discovery of Januvia, Parmee assumed leadership responsibility for an important new diabetes program at Merck, glucagon receptor antagonists. Dr. Parmee's keen attention to detail, clear analytical thinking, and close working relationship with her biological colleagues have played a critical role in her success on that project as well.
In the course of her scientific career, Parmee has been an author or coauthor of 30 papers in refereed journals and is a coinventor on 24 issued and pending patent applications. In addition to Januvia, Parmee has contributed to the discovery of seven development candidates, including one currently in Phase I clinical studies, one in Phase II, and one compound that is expected to enter pivotal Phase III studies later this year. First-rate medicinal chemistry skills and leadership ability have made Parmee a well respected and sought out collaborator in the Merck research community, and hertalents are also known in the worldwide research community.

The Center » Innovation
thecenter.chemheritage.org [cached]

A highlight of the day occurred at lunch when the Gordon E. Moore Medal was presented to Emma Parmee of Merck forher work in the discovery of Januvia, the first and only DPP-4 inhibitor approved for the treatment of type-2 diabetes.

Emma ...
www.chemicalheritage.org, 12 April 2010 [cached]

Emma Parmee

...

Emma Parmee

...

Emma Parmee
Emma Parmee will receive the 2009 SCI Gordon E. Moore Medal for her key role in the discovery of the dipeptidyl peptidase-4 (DPP-4) inhibitor Januvia (sitagliptin), the first and only DPP-4 inhibitor approved for the treatment of type 2 diabetes.

...

Parmee and her colleagues' discovery of the selective DPP-4 inhibitor Januvia represents a major advance in the treatment of type 2 diabetes.

...

Parmee joined Merck following a stellar graduate career atOxford University and a NATO postdoctoral fellowship at theMassachusetts Institute of Technology. She has authored or coauthored 30 papers in refereed journals and is a coinventor on 24 issued and pending patent applications. First-rate medicinal chemistry skills and leadership abilities have made Parmee a well-respected and sought-out collaborator in the Merck research community, and hertalents are also known worldwide.

The Society of Chemical ...
www.chemheritage.org, 21 Aug 2009 [cached]

The Society of Chemical Industry will award the sixth annual Gordon E. Moore Medal to Emma Parmee of Merck and Company to honor her early-career success in discovering the first and only dipeptidyl peptidase-4 (DDP-4) inhibitor for the treatment of type 2 diabetes.

Selected works

• Karim, Sufia; Parmee, Emma R; Thomas, Eric J (May 1991). "Milbemycin synthesis: synthesis of 6β-hydroxy-3,4-dihydromilbemycin E". Tetrahedron Letters 32 (20): 2269–2272.
• Parmee, Emma R; Ok, Hyun O; Candelore, Mari R, et. al. (1998). "Discovery of L-755,507: A subnanomolar human β 3 adrenergic receptor agonist". Bioorganic & Medicinal Chemistry Letters 8 (9): 1107–1112.
• Parmee, Emma R; Naylor, Elizabeth M; Perkins, Leroy, et. al. (1999). "Human β 3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides". Bioorganic & Medicinal Chemistry Letters 9 (5): 749–754.
• Parmee, Emma R; Naylor, Elizabeth M; Perkins, Leroy, et. al. (1999). "Human β 3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides". Bioorganic & Medicinal Chemistry Letters 9 (5): 749–754.
• Mastracchio, Anthony; Parmee, Emma R; Leiting, Barbara, et. al. (May 2004). "Heterocycle-Fused Cyclohexylglycine Derivatives as Novel Dipeptidyl Peptidase-IV Inhibitors".ChemInform 35 (20).
• Parmee, Emma R.; Sinharoy, Ranabir; Xu, Feng; Givand, Jeffrey C.; Rosen, Lawrence A. (2012). "Discovery and Development Of The DPP-4 Inhibitor Januvia™ (Sita-Gliptin)". Case Studies in Modern Drug Discovery and Development. doi:10.1002/9781118219683.ch2.

References

"12th Annual Maria Goeppert-Mayer Interdisciplinary Symposium". Zurich, Switzerland: University of Zurich. 2006. Retrieved 19 November 2015.

"Synthesis of avermectins and milbemycins". British Library. Retrieved 19 November 2015.

"Emma Parmee Gordon E Moore 2009 Medalist". London, England: Society of Chemical Industry. 2009. Retrieved 19 November 2015.

"The Research & Development Council of New Jersey 2007 Thomas Alva Edison Patent Awards". New York Society of Cosmetic Chemists Newsletter (in Mt. Freedom and New Jersey) (New York Society of Cosmetic Chemists) 13 (10): 10. December 2007. Retrieved 19 November 2015.

"31st Annual Tribute to Women and Industry Awards Dinner". Plainfield, New Jersey: YWCA of Central New Jersey. 26 May 2010. Retrieved 19 November 2015.

"Winners Sorted by Medical Field". Neuilly sur Seine, France: Prix Galien. 2015. Retrieved 19 November 2015.

7. "Dr. Emma R. Parmee". Boston, Massachusetts: Harvard University. 2015. Retrieved 19 November 2015.

External links

• WorldCat Publications
• Lancaster University Publications list

https://en.wikipedia.org/wiki/Emma_Parmee